Loading...

CardioGenics Holdings

OTCPK:CGNH
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CGNH
OTCPK
$3M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. The last earnings update was 1148 days ago. More info.


Add to Portfolio Compare Print
  • CardioGenics Holdings has significant price volatility in the past 3 months.
CGNH Share Price and Events
7 Day Returns
26.7%
OTCPK:CGNH
-1.6%
US Biotechs
-0.7%
US Market
1 Year Returns
6.1%
OTCPK:CGNH
-5.5%
US Biotechs
3%
US Market
CGNH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CardioGenics Holdings (CGNH) 26.7% 12.4% 8.6% 6.1% 27.5% -90.3%
US Biotechs -1.6% -5.5% -6.5% -5.5% 9.7% 12%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • CGNH outperformed the Biotechs industry which returned -5.5% over the past year.
  • CGNH outperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for CardioGenics Holdings's competitors could be found in our database.

Value

 Is CardioGenics Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether CardioGenics Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as CardioGenics Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CardioGenics Holdings. This is due to cash flow or dividend data being unavailable. The share price is $0.019.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CardioGenics Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CardioGenics Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:CGNH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2016-01-31) in USD Not available
OTCPK:CGNH Share Price ** OTCPK (2019-05-17) in USD $0.02
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.48x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CardioGenics Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for CardioGenics Holdings, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does CardioGenics Holdings's expected growth come at a high price?
Raw Data
OTCPK:CGNH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.32x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CardioGenics Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CardioGenics Holdings's assets?
Raw Data
OTCPK:CGNH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2016-01-31) in USD Not available
OTCPK:CGNH Share Price * OTCPK (2019-05-17) in USD $0.02
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.21x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x

* Primary Listing of CardioGenics Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Take a look at our analysis of CGNH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess CardioGenics Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CardioGenics Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CardioGenics Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CardioGenics Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CardioGenics Holdings expected to grow at an attractive rate?
  • Unable to compare CardioGenics Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare CardioGenics Holdings's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare CardioGenics Holdings's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:CGNH Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:CGNH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:CGNH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2016-01-31 0 -1
2015-10-31 -1 -2
2015-07-31 -1 -3
2015-04-30 0 -3
2015-01-31 -1 -3
2014-10-31 -1 -3
2014-07-31 -1 -3
2014-04-30 -1 -3
2014-01-31 -1 -3
2013-10-31 -1 -3
2013-07-31 0 -1 -1
2013-04-30 0 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if CardioGenics Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if CardioGenics Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:CGNH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from CardioGenics Holdings Company Filings, last reported 3 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CGNH Past Financials Data
Date (Data in USD Millions) EPS *
2016-01-31 -0.01
2015-10-31 -0.02
2015-07-31 -0.04
2015-04-30 -0.04
2015-01-31 -0.05
2014-10-31 -0.04
2014-07-31 -0.06
2014-04-30 -0.05
2014-01-31 -0.05
2013-10-31 -0.05
2013-07-31 -0.02
2013-04-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CardioGenics Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of CGNH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. CardioGenics Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access CardioGenics Holdings's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess CardioGenics Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CardioGenics Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CardioGenics Holdings performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, CardioGenics Holdings has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • CardioGenics Holdings's last earnings update was 1148 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CardioGenics Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if CardioGenics Holdings's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare CardioGenics Holdings's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare CardioGenics Holdings's 1-year growth to the US Biotechs industry average as past earnings data has not been reported.
Earnings and Revenue History
CardioGenics Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CardioGenics Holdings Company Filings, last reported 3 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CGNH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2016-01-31 -0.98 0.55 0.21
2015-10-31 -1.92 0.54 0.22
2015-07-31 -2.92 0.34 0.41
2015-04-30 -2.87 0.40 0.45
2015-01-31 -3.33 0.41 0.48
2014-10-31 -2.68 0.45 0.50
2014-07-31 -3.48 1.92 0.41
2014-04-30 -3.23 1.95 0.41
2014-01-31 -3.10 1.95 0.40
2013-10-31 -2.92 1.89 0.42
2013-07-31 0.00 -1.12 0.57 0.39
2013-04-30 0.00 -1.04 0.59 0.37
2013-01-31 0.00 -1.22 0.68 0.47
2012-10-31 0.00 -1.31 0.74 0.52
2012-07-31 0.00 -3.28 2.96 0.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if CardioGenics Holdings has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if CardioGenics Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if CardioGenics Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at CardioGenics Holdings's management and board experience and expertise to assess their ability to deliver on their strategic promises.
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access CardioGenics Holdings's filings and announcements here.
  3. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess CardioGenics Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CardioGenics Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CardioGenics Holdings's financial health and their level of debt?

In this section we usually analyse CardioGenics Holdings's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. CardioGenics Holdings has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CardioGenics Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as CardioGenics Holdings has not reported sufficient balance sheet data.
  • Unable to establish if CardioGenics Holdings's long term commitments exceed its cash and other short term assets as CardioGenics Holdings has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of CardioGenics Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if CardioGenics Holdings has a high level of physical assets or inventory without balance sheet data.
  • Unable to verify if debt is covered by short term assets as CardioGenics Holdings has not reported sufficient balance sheet data.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CardioGenics Holdings Company Filings, last reported 3 years ago.

OTCPK:CGNH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2016-01-31 -1.79 0.38 0.10
2015-10-31 -1.56 0.21 0.05
2015-07-31 -1.63 0.13 0.05
2015-04-30 -1.32 0.21 0.04
2015-01-31 -1.55 0.22 0.08
2014-10-31 -1.16 0.20 0.07
2014-07-31 -1.73 0.54 0.06
2014-04-30 -1.21 0.43 0.05
2014-01-31 -0.95 0.37 0.17
2013-10-31 -0.92 0.32 0.26
2013-07-31 -0.49 0.29 0.41
2013-04-30 -0.85 0.23 0.29
2013-01-31 -0.73 0.30 0.23
2012-10-31 -0.51 0.10 0.08
2012-07-31 -0.40 0.27 0.12
  • Unable to establish if CardioGenics Holdings's level of debt is high without past debt data.
  • Unable to establish if CardioGenics Holdings's debt level has increased without past 5-year debt data.
  • Unable to verify if debt is well covered by operating cash flow as CardioGenics Holdings has not reported sufficient balance sheet data.
  • Unable to confirm if the interest payments on CardioGenics Holdings's debt are well covered by earnings due to lack of past financial data.

Next steps:

  1. Take a look at our analysis of CGNH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  3. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when CardioGenics Holdings's financial data was last updated here.
  4. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  5. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess CardioGenics Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CardioGenics Holdings has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CardioGenics Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CardioGenics Holdings dividends.
If you bought $2,000 of CardioGenics Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CardioGenics Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CardioGenics Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:CGNH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CardioGenics Holdings has not reported any payouts.
  • Unable to verify if CardioGenics Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CardioGenics Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CardioGenics Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CardioGenics Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CardioGenics Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CardioGenics Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CardioGenics Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yahya Gawad
COMPENSATION $119,449
AGE 60
TENURE AS CEO 22.3 years
CEO Bio

Dr. Yahia A. Gawad, MB, Ch.B., MD, MSc. has been Chief Executive Officer of CardioGenics Holdings Inc. (formerly, JAG Media Holdings Inc.) since 1997. Dr. Gawad served as the Chief Medical Officer at MB Holding Company LLC until May 11, 2016. He has extensive experience in the following departments in Khoula Hospital- Sultanate of Oman - Accident and Emergency, Orthopaedic, General Surgery, Plastic and Hand-Surgery and Uro-Surgery. Dr. Gawad's academic and commercial experience and expertise include many years of designing and managing cardiovascular disease research and product development. He served as a Medical Officer In Charge at Khoula Hospital since 1999 and also served as its Assistant to the Hospital Director. Dr. Yahya was actively involved in the 5 year plan for improving emergency services in Oman. Dr. Gawad co-founded a division of Nanogen (NGEN) (formerly, Syn X and Skye Pharmatech), where he served as Vice-President, Medical Affairs. Prior to that, he served as Director of Clinical Research and Development at Spectral Diagnostics Inc. (now Nanogen). For 16 years, he served extensively on cardiac diagnostic test products. He has been a Director of CardioGenics since 1997. He was a Reviewer for the editorial board of the American Journal of Cardiology from 1999 to 2003. He was a Member of both the Clinical Committee of the American Heart Association and the POC division of the American Association for Clinical Chemistry. He has prepared, submitted and obtained FDA regulatory approvals for several cardiac test products currently being marketed (including Cardiac Status Troponin I®, Myoglobin® and Myoglobin/CK-MB®, registered trademarks of Spectral Diagnostics Inc.). In addition, Dr. Gawad has researched, developed and published several other tests. Dr. Gawad published extensively and presented his research and clinical findings at national and international symposia. Dr. Gawad has received several awards and scholarships. Dr. Gawad is a Physician/Scientist with primary training in Cardiology, Biochemistry and Immunology. He is certified from Ronald Reagan Institute of Emergency Medicine in USA for Advanced Trauma Life Support and advanced cardiac life support. He received his medical education and post-graduate training at the University of Toronto. He holds a Degree in Medicine and Surgery from Alexandria University in Egypt, and a Diploma in Occupational Medicine from the Royal Society of Public Health in London, UK.

CEO Compensation
  • No earnings data for CardioGenics Holdings, not possible to compare to compensation.
  • Insufficient data for Yahya to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the CardioGenics Holdings management team in years:

18.3
Average Tenure
60
Average Age
  • The average tenure for the CardioGenics Holdings management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yahya Gawad

TITLE
Chief Executive Officer and Director
COMPENSATION
$119K
AGE
60
TENURE
22.3 yrs

James Essex

TITLE
Chief Financial Officer
COMPENSATION
$29K
AGE
69
TENURE
18.3 yrs

Linda Stering

TITLE
Secretary & Director
AGE
57
TENURE
16.3 yrs
Board of Directors Tenure

Average tenure and age of the CardioGenics Holdings board of directors in years:

9.6
Average Tenure
60
Average Age
  • The tenure for the CardioGenics Holdings board of directors is about average.
Board of Directors

Julian Tabatznik

TITLE
Acting Chairman
AGE
68
TENURE
10.3 yrs

Yahya Gawad

TITLE
Chief Executive Officer and Director
COMPENSATION
$119K
AGE
60
TENURE
22.3 yrs

Linda Stering

TITLE
Secretary & Director
AGE
57
TENURE
10.3 yrs

William Kostuk

TITLE
Member of Scientific Advisory Board
TENURE
8.9 yrs

Bob Roberts

TITLE
Member of Scientific Advisory Board
AGE
77
TENURE
8.9 yrs

Karim Murabet

TITLE
Independent Director
AGE
60
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess CardioGenics Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CardioGenics Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

Details
Name: CardioGenics Holdings Inc
CGNH
Exchange: OTCPK
Founded: 1997
$2,666,876
140,361,946
Website: http://www.cardiogenics.com
Address: CardioGenics Holdings Inc
6295 Northam Drive,
Unit 8,
Mississauga,
Ontario, L4V 1W8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK CGNH Common Stock Pink Sheets LLC US USD 03. Aug 2009
Number of employees
Current staff
Staff numbers
0
CardioGenics Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 01:56
End of day share price update: 2019/05/17 00:00
Last earnings filing: 2016/03/28
Last earnings reported: 2016/01/31
Last annual earnings reported: 2015/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.